Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Pirtobrutinib Showcases Encouraging Activity in CLL, MCL, and Other B-Cell Malignancies

April 8th 2021

Pirtobrutinib showcased encouraging efficacy with an acceptable safety profile in patients with chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia who previously received a BTK inhibitor.

Dr. Barr on the Safety Profile of Umbralisib/Ublituximab/Venetoclax in CLL

April 8th 2021

Paul M. Barr, MD, discusses the safety profile of umbralisib plus ublituximab and venetoclax in chronic lymphocytic leukemia.

Dr. Shadman on Considerations for BTK inhibitors in CLL

April 7th 2021

Mazyar Shadman, MD, discusses considerations for BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Dr. Bociek on the Clinical Uncertainty of MRD Negativity in CLL

April 6th 2021

R. Gregory Bociek, MD, discusses the clinical uncertainty of minimal residual disease negativity in chronic lymphocytic leukemia.

Dr. Shadman on Continuous Vs Time-Limited Treatments in CLL

April 2nd 2021

Mazyar Shadman, MD, discusses continuous vs time-limited treatments for patients with chronic lymphocytic leukemia.

Duvelisib Granted Positive EU Opinion for Relapsed/Refractory CLL and Refractory Follicular Lymphoma

April 1st 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of single-agent duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia following at least 2 prior therapies, and follicular lymphoma that is refractory to at least 2 prior systemic treatments.

Rolling Submission of BLA to FDA Completed for Ublituximab/Umbralisib in CLL

March 29th 2021

The rolling submission of a biologics license application to support the approval of ublituximab plus umbralisib as a treatment for patients with chronic lymphocytic leukemia has been completed.

Dr. Mead on the Role of BTK Inhibition After Venetoclax in Relapsed/Refractory CLL

March 12th 2021

Monica D. Mead, MD, discusses the role of BTK inhibition after venetoclax in relapsed/refractory chronic lymphocytic leukemia.

Pushing Toward Time-Limited Options and More Tolerable PI3K Inhibitors in CLL

March 12th 2021

Seema A. Bhat, MD, discusses updates from key studies and highlighted the promise of novel PI3K inhibitors in chronic lymphocytic leukemia.

Dr. Bociek on the Role of MRD in CLL

March 11th 2021

R. Gregory Bociek, MD, discusses the role of minimal residual disease in patients with chronic lymphocytic leukemia.

Dr. Mead on Ongoing Research Efforts to Overcome BTK Inhibitor Resistance in CLL

March 9th 2021

Monica D. Mead, MD, discusses ongoing research efforts to overcome BTK inhibitor resistance in patients with chronic lymphocytic leukemia.

Frontline Ibrutinib Shows Sustained Survival Benefit in TP53-Aberrant CLL

March 8th 2021

Ibrutinib as a frontline treatment led to sustained efficacy and impressive 4-year progression-free and overall survival rates in patients with chronic lymphocytic leukemia who have TP53 aberrations.

Dr. Mead on the Utility of Second-Line Venetoclax/Rituximab in CLL

March 5th 2021

Monica D. Mead, MD, discusses the utility of venetoclax in combination with rituximab in the second-line setting for patients with chronic lymphocytic leukemia.

Dr. Bociek on Reserving Allo-SCT for Certain Patients with CLL

March 4th 2021

R. Gregory Bociek, MD, discusses the rationale to reserve allogeneic stem cell transplant for certain patients with chronic lymphocytic leukemia.

Dr. Shadman on the Role of MRD in CLL

March 3rd 2021

Mazyar Shadman, MD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.

Brown Breaks Down How to Choose the Optimal Frontline Approach for CLL

March 3rd 2021

The treatment paradigm for chronic lymphocytic leukemia has expanded beyond continuous treatment with BTK inhibitors with the addition of the time-limited regimen of venetoclax plus obinutuzumab.

Dr. Bociek on Outcomes of Patients With CLL and COVID-19

March 2nd 2021

R. Gregory Bociek, MD, discusses outcomes for patients with chronic lymphocytic leukemia and COVID-19.

Targeted Therapies Dominate the Relapsed/Refractory CLL Paradigm

February 27th 2021

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

Explosion of Data Come From Innovative Combos in CLL

February 26th 2021

The progress made with novel combination regimens coupled with their game-changing data in both frontline and relapsed/refractory chronic lymphocytic leukemia is unprecedented.

Cirmtuzumab/Ibrutinib Shows Encouraging Clinical Activity, Safety in MCL and CLL

February 26th 2021

Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.